welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
Sarepta Therapeutics and Jerry R. Mendell, M.D. to Provide Update on Duchenne Muscular Dystrophy Gene Therapy Program from the 23rd International Annual Congress of the World Muscle Society
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, and Jerry R. Mendell, M.D., Curran-Peters Chair of Pediatric Research and Professor of Pediatrics and Neurology, Nationwide Children’s Hospital and The Ohio State University; The Research Institute at Nationwide Children’s Hospital, will host a webcast conference call from the 23rd International Annual Congress of the World Muscle Society (WMS) in Mendoza, Argentina, on Thursday, October 4, 2018 at 7:00 a.m. Eastern Time / 8:00 a.m. local Argentina time. The call will focus on an update regarding Sarepta’s Duchenne muscular dystrophy (DMD) micro-dystrophin gene therapy program and will be led by Dr. Mendell, a renowned researcher in the field of DMD.
rareRelated
-
International Annual Congress of the World Muscle SocietyWe are delighted to invite you to atte...
-
Muscular Dystrophy Association CA – Camp HarmonThis session has openings for males and ...
-
A Randomized, Double-blind, Placebo-controlled Study of SRP-9001 for Duchenne Muscular Dystrophy (DMD)The purpose of this study is to evaluate...
-
Study of DS-5141b in Patients With Duchenne Muscular DystrophyThis is a phase I/II study to evaluate t...
-
George Dickson, PhDGeorge Dickson is Professor of Molecular...
-
Emerging Therapies for Duchenne Muscular Dystrophyhttps://www.youtube.com/watch?v=4qtcyz4U...
-
Results of North Star Ambulatory Assessments (NSAA) in the Phase 3 Ataluren Confirmatory Trial in Patients with Nons...Objective: Examine the efficacy of atal...